Updates on cardiovascular outcome trials in diabetes
Abstract In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications.Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high 123 cardiovascular risk for members of the SGLT-2 and DPP